Company intelligence / Profile preview

Protea Vaccine Technologies Ltd.

Kiryat Shmona/Ness Ziona/Beer-Sheva*, Israelwipo.int ↗

Ownership: Private
Development stage: Preclinical

Overview

Developed a proprietary platform to identify conserved pneumococcal proteins that confer protective immunity in preclinical mouse models. Entered into a research and license option agreement with GlaxoSmithKline (GSK) for further development; no clinical results reported as of the latest updates.

Therapeutic areas: Infectious Diseases
Modalities: Protein-based vaccines
Industry: Biotech

Drug pipeline

1 asset

Pneumococcal conjugate vaccine

Pre-clinical

Indications: Pneumococcal infection

Partnerships

GlaxoSmithKline Biologicals S.A. – exclusive research and license option agreement for universal protein-based pneumococcal vaccine development and commercialization

Beyond the preview

Go deeper on Protea Vaccine Technologies Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protea Vaccine Technologies Ltd..

Explore the full profile